Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7526274rdf:typepubmed:Citationlld:pubmed
pubmed-article:7526274lifeskim:mentionsumls-concept:C0007578lld:lifeskim
pubmed-article:7526274lifeskim:mentionsumls-concept:C1749467lld:lifeskim
pubmed-article:7526274lifeskim:mentionsumls-concept:C0264939lld:lifeskim
pubmed-article:7526274lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:7526274pubmed:issue7lld:pubmed
pubmed-article:7526274pubmed:dateCreated1994-11-28lld:pubmed
pubmed-article:7526274pubmed:abstractTextThe plasma levels of soluble intercellular adhesion molecule-1 (sICAM-1), E-selectin (sE-selectin), and vascular cell adhesion molecule-1 (sVCAM-1), might reflect endothelial activation and injury and would therefore be useful markers of disease activity in vasculitis. To investigate this we measured the levels of sICAM-1, sE-selectin, and sVCAM-1 by two-site ELISAs in the plasma of patients with (a) active vasculitis (n = 16), (b) vasculitis in remission (n = 15), (c) chronic renal failure (CRF) (n = 10), and (d) normal healthy controls (n = 10). Plasma sICAM-1 levels were significantly higher in patients with active vasculitis, 323 ng/ml (193-607) compared with patients with inactive vasculitis, 199 ng/ml (131-297); P = 0.0006 and healthy controls, 188 ng/ml (138-259); P = 0.0002. Plasma sE-selectin levels were also significantly higher in the patients with active vasculitis, 45 ng/ml (15-65) compared with patients with inactive vasculitis, 25 ng/ml (15-55); P = 0.027 but not when compared with healthy controls, 35 ng/ml (20-55); P = 0.16. There was no difference in plasma sVCAM-1 levels between patients with active vasculitis, OD 0.56 (0.45-0.85) and inactive disease, OD 0.58 (0.47-0.79) (P = 0.12) or with healthy controls OD 0.49 (0.42-0.68) (P = 0.48). There were no significant differences between the plasma levels of any of the soluble adhesion molecules between patients with active vasculitis and patients with chronic failure.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7526274pubmed:languageenglld:pubmed
pubmed-article:7526274pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:citationSubsetIMlld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7526274pubmed:statusMEDLINElld:pubmed
pubmed-article:7526274pubmed:issn0931-0509lld:pubmed
pubmed-article:7526274pubmed:authorpubmed-author:TaylorC MCMlld:pubmed
pubmed-article:7526274pubmed:authorpubmed-author:MichaelJJlld:pubmed
pubmed-article:7526274pubmed:authorpubmed-author:AduDDlld:pubmed
pubmed-article:7526274pubmed:authorpubmed-author:RichardsN TNTlld:pubmed
pubmed-article:7526274pubmed:authorpubmed-author:PalsA JAJlld:pubmed
pubmed-article:7526274pubmed:authorpubmed-author:DraysonMMlld:pubmed
pubmed-article:7526274pubmed:issnTypePrintlld:pubmed
pubmed-article:7526274pubmed:volume9lld:pubmed
pubmed-article:7526274pubmed:ownerNLMlld:pubmed
pubmed-article:7526274pubmed:authorsCompleteYlld:pubmed
pubmed-article:7526274pubmed:pagination770-4lld:pubmed
pubmed-article:7526274pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:meshHeadingpubmed-meshheading:7526274-...lld:pubmed
pubmed-article:7526274pubmed:year1994lld:pubmed
pubmed-article:7526274pubmed:articleTitleCirculating soluble adhesion molecules in systemic vasculitis.lld:pubmed
pubmed-article:7526274pubmed:affiliationRenal Research Laboratories, Queen Elizabeth Hospital, Edgbaston, Birmingham, University of Birmingham, Birmingham, UK.lld:pubmed
pubmed-article:7526274pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7526274lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7526274lld:pubmed